These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6863572)

  • 21. The effect of vindesine therapy on the in vitro immune response of patients with advanced malignant melanoma.
    Retsas S; Thomas C; Hobbs JR
    Clin Oncol; 1981 Mar; 7(1):33-7. PubMed ID: 7214761
    [No Abstract]   [Full Text] [Related]  

  • 22. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
    Osterlind K; Dombernowsky P; Sørensen PG; Hansen HH
    Cancer Treat Rep; 1981; 65(3-4):245-8. PubMed ID: 6263469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update results of vindesine as a single agent in the therapy of advanced malignant melanoma.
    Retsas S; Peat I; Ashford R; Coe M; Maher J; Drury A; Hanham IW; Phillips RH; Newton KA; Westbury G
    Cancer Treat Rev; 1980 Sep; 7 Suppl 1():87-90. PubMed ID: 7438128
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II study of vindesine in patients with Hodgkin's disease, lymphoma, and breast cancer.
    Gad-El-Mawla N; Hamza MR; El-Serafi M; El-Khoudary A; Aboul-Einein M; El-Demerdash S
    Cancer Treat Rep; 1983 Mar; 67(3):316-7. PubMed ID: 6831481
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II trial of vindesine in advanced head and neck cancer.
    Cheng E; Young CW; Wittes RE
    Cancer Treat Rep; 1980; 64(10-11):1141-2. PubMed ID: 7459901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vindesine in oral cancers].
    Szpirglas H; Marneur M; Vaillant JM
    Presse Med; 1985 Feb; 14(7):405-7. PubMed ID: 3157128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proceedings of the 7th Lilly Vinca Alkaloid Symposium on Vindesine Washington, D.C., 6-7 October 1979.
    Cancer Treat Rev; 1980 Sep; 7 Suppl 1():1-93. PubMed ID: 7438116
    [No Abstract]   [Full Text] [Related]  

  • 28. EORTC phase II trial of vindesine in advanced melanoma.
    Rümke P; Everall JD; Mulder JH; Rozencweig M; Czarnetzki B; Thomas D
    Eur J Cancer Clin Oncol; 1983 Aug; 19(8):1173-4. PubMed ID: 6684562
    [No Abstract]   [Full Text] [Related]  

  • 29. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
    Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections.
    Rahmani R; Martin M; Favre R; Cano JP; Barbet J
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1409-17. PubMed ID: 6542010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of vindesine in patients with metastatic breast cancer.
    Cobleigh MA; Williams SD; Einhorn LH
    Cancer Treat Rep; 1981; 65(7-8):659-63. PubMed ID: 7248983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II evaluation of vindesine for patients with advanced colorectal carcinoma.
    Saiers JH; Slavik M; McKinney DR
    Cancer Treat Rep; 1982 Mar; 66(3):583-4. PubMed ID: 7060047
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II evaluation of vindesine in patients with advanced breast cancer.
    Currie VE; Camacho F; Wittes R; Young C
    Cancer Treat Rep; 1980; 64(4-5):693-95. PubMed ID: 7427954
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of esophageal cancer with vindesine: an open trial.
    Bezwoda WR; Derman DP; Weaving A; Nissenbaum M
    Cancer Treat Rep; 1984 May; 68(5):783-5. PubMed ID: 6722833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vindesine in plasma cell tumors.
    Salvagno L; Paccagnella A; Chiarion Sileni V; De Besi P; Frizzarin M; Casara D; Fiorentino MV
    Tumori; 1985 Dec; 71(6):533-6. PubMed ID: 4082286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
    Colombi M; Guffanti A; Alietti A; Latargia ML; Vener C; Maiolo AT; Baldini L
    Leuk Lymphoma; 2000 Dec; 40(1-2):87-94. PubMed ID: 11426632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phase II study of Vindesine in patients with hematological malignancy].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1536-7. PubMed ID: 6347082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
    Massner B; Voss I; Queisser W; Drings P; Fritze D; Westerhausen M
    Onkologie; 1982 Aug; 5 Suppl():46-51. PubMed ID: 6752791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of vindesine in metastatic malignant melanoma.
    Arseneau JC; Mellette SJ; Kuperminc M; Wolter J
    Cancer Treat Rep; 1981; 65(3-4):355-6. PubMed ID: 7237458
    [No Abstract]   [Full Text] [Related]  

  • 40. A 125I-radiolabelled probe for vinblastine and vindesine radioimmunoassays: applications to measurements of vindesine plasma levels in man after intravenous injections and long-term infusions.
    Rahmani R; Barbet J; Cano JP
    Clin Chim Acta; 1983 Mar; 129(1):57-69. PubMed ID: 6851151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.